Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almotriptan vs Ubrogepant for Acute Migraine
NCT05214001Phase 4Terminated
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of almotriptan in migraine (2 arms). Primary endpoint: Pain freedom at 2 hours. Started Jun 2022; status: terminated.
02
Drugs
almotriptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05214001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214001.